Rejoni

Rejoni, Inc. is a privately held, clinical-stage women's health medical device company founded in June 2020 by serial entrepreneur Amar Sawhney, PhD and Pramand LLC, and headquartered at 201 Burlington Road in Bedford, Massachusetts. It develops proprietary hydrogel-based biomaterial therapies for gynecological surgery, with a stated mission of protecting, preserving and healing the uterus. Its lead product, the Juveena Hydrogel System, is designed to prevent the formation and reformation of intrauterine adhesions (IUAs) — the scar tissue that forms after transcervical procedures such as dilation and curettage, myomectomy or treatment of heavy bleeding, and a leading cause of infertility and abnormal uterine bleeding. The system pairs a low-profile proprietary transcervical catheter with two liquid precursors that cross-link on delivery into a soft, temporary hydrogel implant that mechanically separates the uterine walls during healing and then resorbs on its own in roughly two to three weeks, about one menstrual cycle, so no removal procedure is required. Juveena is investigational only and pending FDA approval; the FDA filed Rejoni's premarket approval (PMA) application in January 2026, and the company completed patient enrollment in its US IDE pivotal study. Rejoni closed a $25 million financing in June 2026 with ClavystBio, Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta Group, and appointed women's health MedTech leader John Nealon as chief executive officer in May 2026. Rejoni runs no developer program and publishes no public API: its entire web presence is a small Webflow marketing site, and probes for OpenAPI, Swagger, GraphQL, MCP, llms.txt and every /.well-known/ discovery path returned HTTP 404 against a verified real-404 origin, while api./developer./docs./app./portal.rejoni.com resolve only to a wildcard A record with no listener answering on either port 80 or 443.

Rejoni is profiled on the APIs.io network. Tagged areas include Company, Medical Devices, Women’s Health, Healthcare, and Biomaterials.

Rejoni’s developer surface includes product news and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub

8.5/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyMedical DevicesWomen's HealthHealthcareBiomaterialsLife SciencesSurgeryClinical TrialsMedTech

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 8.5/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 0.0 / 17

Commercial Clarity 1.8 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 1.9 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/rejoni: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Contact

Contact

Commercial 1

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

Company 4

The organization behind the API

Website

Website

About

About

News

News

LinkedIn

Other 3

Properties that don't map to a standard resource type

Team

Team

Technology

Technology

SecondaryMarket

SecondaryMarket

Source (apis.yml)

aid: rejoni
name: Rejoni
image: https://cdn.prod.website-files.com/68a338214a8d0f9a68a471b5/68a360063a1179d6ecb188ec_Rejoni_tag_logo_White.svg
description: 'Rejoni, Inc. is a privately held, clinical-stage women''s health medical device company founded in June 2020
  by serial entrepreneur Amar Sawhney, PhD and Pramand LLC, and headquartered at 201 Burlington Road in Bedford, Massachusetts.
  It develops proprietary hydrogel-based biomaterial therapies for gynecological surgery, with a stated mission of protecting,
  preserving and healing the uterus. Its lead product, the Juveena Hydrogel System, is designed to prevent the formation and
  reformation of intrauterine adhesions (IUAs) — the scar tissue that forms after transcervical procedures such as dilation
  and curettage, myomectomy or treatment of heavy bleeding, and a leading cause of infertility and abnormal uterine bleeding.
  The system pairs a low-profile proprietary transcervical catheter with two liquid precursors that cross-link on delivery
  into a soft, temporary hydrogel implant that mechanically separates the uterine walls during healing and then resorbs on
  its own in roughly two to three weeks, about one menstrual cycle, so no removal procedure is required. Juveena is investigational
  only and pending FDA approval; the FDA filed Rejoni''s premarket approval (PMA) application in January 2026, and the company
  completed patient enrollment in its US IDE pivotal study. Rejoni closed a $25 million financing in June 2026 with ClavystBio,
  Amed Ventures, Ascension Ventures, Catalyst Health Ventures, Delos Capital, FemHealth Ventures, Iyengar Capital and Sparta
  Group, and appointed women''s health MedTech leader John Nealon as chief executive officer in May 2026. Rejoni runs no developer
  program and publishes no public API: its entire web presence is a small Webflow marketing site, and probes for OpenAPI,
  Swagger, GraphQL, MCP, llms.txt and every /.well-known/ discovery path returned HTTP 404 against a verified real-404 origin,
  while api./developer./docs./app./portal.rejoni.com resolve only to a wildcard A record with no listener answering on either
  port 80 or 443.'
url: https://raw.githubusercontent.com/api-evangelist/rejoni/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-05'
modified: '2026-08-05'
tags:
- Company
- Medical Devices
- Women's Health
- Healthcare
- Biomaterials
- Life Sciences
- Surgery
- Clinical Trials
- MedTech
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: Website
  url: https://rejoni.com/
- type: About
  url: https://rejoni.com/about
- type: Team
  url: https://rejoni.com/team
- type: Technology
  url: https://rejoni.com/technology
- type: News
  url: https://rejoni.com/news
- type: Contact
  url: https://rejoni.com/contact
- type: PrivacyPolicy
  url: https://rejoni.com/privacy
- type: LinkedIn
  url: https://www.linkedin.com/company/rejoni
- type: SecondaryMarket
  url: https://forgeglobal.com/rejoni_stock/
- type: DomainSecurity
  url: security/rejoni-domain-security.yml
- type: LLMsTxt
  url: llms/rejoni-llms.txt
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Rejoni's product is a resorbable hydrogel implant and a transcervical delivery catheter pending FDA premarket approval,
    not software; its whole web presence is a seven-page Webflow marketing site with an empty robots.txt, where /openapi.json,
    /graphql, /mcp, /llms.txt and every /.well-known/ path 404 against a verified real-404 control, and api./developer./docs.rejoni.com
    resolve only to a wildcard A record that never answers a TCP connect.
  evidence:
  - url: https://rejoni.com/openapi.json
    status: 404
  - url: https://rejoni.com/llms.txt
    status: 404
  - url: https://rejoni.com/.well-known/agent-card.json
    status: 404
  - url: https://rejoni.com/graphql
    status: 404
  - url: https://rejoni.com/zzz-control-path-check
    status: 404
  - url: https://api.rejoni.com/
    status: 0
  checked: '2026-08-05'
x-enrichment:
  date: '2026-08-05'
  status: minimal
  artifacts_added: 3
  pass: local-v1